medigraphic.com
Coordinación General de Investigación de la Facultad de Salud Pública y Nutrición y la Dirección General de Sistemas e Informática de la Universidad Autónoma de Nuevo León

2011, Number 1

<< Back

Rev Salud Publica Nutr 2011; 12 (1)

Linfedema secundario a cáncer de mama: ¿Una posible secuela a considerar?

Jiménez-Pérez LM, Zepeda-Ornelas EA, Laguna-Macías PK, Frías-Terrones MG, Meza-León B

Language: Spanish
References: 72
Page:
PDF size: 84.74 Kb.


ABSTRACT

Breast cancer is still the most common neoplasy among women. Important changes for its treatment approaches have been observed recently, thinking that Lymphedema Secondary to Breast Cancer (BCRL) was an old issue. Even it was thought that no cases of this sequela would occur with the incorporation of the sentinel lymph node biopsy technique, however, recent reports have shown BCRL rates between 4 – 17%. In addition, it is possible that BCRL is being underestimated, since many women, in spite of having the problem, do not demand medical care, and because of the absence of a convenient, objective and standardized diagnostic method. Many scientific and internationally published articles about this topic rise attention that BCRL is still an important problem to consider among breast cancer survivors, because of its frequency and the impact that it might have on different aspects of life (physical, psychological and social). In addition, it is important to recognize, breast cancer survivors remain at risk of this health problem for lifetime; and once it has clinically settled down, it might become a chronic and irreversible condition, although controllable with the right medical management, which implies higher costs. A remarkable notice is the increasing research on prevention, diagnosis and treatment of BCRL. In Mexico, current official breast cancer norm, does not include lymphedema as a consequence of this type of cancer. Its possible occurrence must be taken into account at first, among health personnel and eventually, patients should receive this information, for being aware and pertinent actions could be taken for prevention and opportune care.


REFERENCES

  1. Porter P. L. 2009. Global trends in breast cancer incidence and mortality. Salud Publica Mex. Vol 52, Sup. 2: S141 -S146.

  2. Parkin D.M., F Bray, J. Ferlay and P. Pisani. 2002. Global cancer statistics.CA Cancer J Clin 2005; 55(2):74-108.

  3. Frenk J. 2009. Sensibilización, detección temprana y combate a los prejuicios. Salud Publica Mex. Vol 52, Sup. 2: S135-S137.

  4. Paskett E. D. 2008. Breast cancer-related lymphedema: attention to a significant problem resulting from cancer diagnosis. J Clin Oncol 26(35): 5666-7.

  5. Armer J. M. 2005. The problem of post-breast cancer lymphedema: impact and measurement issues. Cancer Invest 23(1): 76-83.

  6. Armer J. and M. R. Fu. 2005. Age differences in post-breast cancer lymphedema signs and symptoms. Cancer Nurs 28(3): 200-7; quiz 208-9.

  7. Fu M. R., S. H. Ridner and J. Armer. 2009. Post-breast cancer. Lymphedema: part 1. Am J Nurs. 2009 Jul; 109 (7):48-54).

  8. Porter P. L. Op. cit.

  9. Idem.

  10. Idem

  11. Frenk J. Op. Cit.

  12. Porter, P. L. Op. cit.

  13. Martínez-Montañez O. G., P. Uribe-Zúñiga y M. Hernández-Ávila. 2009. Políticas públicas para la detección del cáncer de mama en México. Salud Publica Mex. Vol 52, Sup. 2: S350-S360.

  14. Palacio-Mejía E. LSL-P, B. Allen-Leigh y M. Hernández-Ávila. 2009. Diferencias regionales en la mortalidad por cáncer de mama y cérvix en México entre 1979 y 2006. Salud Pública de México. 2009;51:208-19

  15. Martínez-Montañez O. G., et al. Op Cit.

  16. Rodríguez-Cuevas S, C.G. Macías-Martínez and S. Labastida-Almendaro. 2000. Breast cancer in Mexico. Is it a young women disease? Ginecol Obstet Mex. 2000 May; 68:185-90.

  17. Linnitt N. and H. Young. 2007. The complexities of managing breast oedema. Br J Community Nurs 12(11513-7.

  18. Ridner S. H. 2005. Quality of life and a symptom cluster associated with breast cancer treatment-related lymphedema. Support Care Cancer 13(11): 904-11.

  19. Linnitt N. 2005. Lymphedema: recognition, assessment and management. Br J Community Nurs 10(3): S20-6.

  20. Idem.

  21. Armer J. M., M. E. Radina, et al. 2003. Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res 52(6): 370-9.

  22. Armer J. M. and B. R. Stewart. 2005. A comparison of four diagnostic criteria for Lymphedema in a post-breast cancer population. Lymphat Res Biol 3(4): 208-17.

  23. Armer J. M., M. E. Radina, et al. Op. cit.

  24. Armer J. M. and B. R. Stewart. Op. cit.

  25. Fu M. R., S. H. Ridner and J. Armer. Op. cit.

  26. Armer J. M. Op. Cit.

  27. 27.Schmitz K. H. 2010 Balancing Lymphedema risk: exercise versus deconditioning for breast cancer. Exerc Sport Sci Rev. 2010 Jan;38(1):17-24

  28. Fleysher L.A. 2010. Keeping Breast Cancer Survivors Lymphedema Free. Br J Nurs. 2010 Jul 8-21; 19(13):826- 30).

  29. Fu M. R., S. H. Ridner and J. Armer. Op. cit.

  30. Armer J. and M. R. Fu. Op. cit.

  31. Piller N., V. Keeley. T. Ryan, S. Hayes, S. Ridner. 2009. Early detection — a strategy to reduce risk and severity? Journal of Lymphoedema, 2009, Vol. 4, No 1

  32. Consensus document of the international society of Lymphology. 2009. The diagnosis and treatment of peripheral Lymphedema. Lymphology 42: 51-60

  33. Thiadens, S.R.J., P. J. Stewart and N. L. Stout 2010. 100 Questions & Answers about Lymphedema. Jones and Bartlett Publishers. 178.

  34. Fu M. R., S. H. Ridner and J. Armer. Op. cit.

  35. Cormier J. N., R. L. Askew, K. S. Mungovan, Y. Xing, M. I. Ross and J. M. Armer. 2010. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary Lymphedema. Cancer Month. 2010 Nov 15; 116 (22):5138-49.

  36. Consensus document of the international society of Lymphology. Op. cit.

  37. Francis W.P., P. Abghari, W. Du, C. Rymal, M. Suna, M.A. Kosir. 2006. Improving surgical outcomes: standardizing the reporting of incidence and severity of acute Lymphedema after sentinel lymph node biopsy and axillary lymph node dissection. Am. J. Surg. 2006; 192:636-9.

  38. Harmer V. 2009. Breast cancer-related lymphoedema: implications for primary care. Br J Community Nurs. 2009 Oct; 14(10):S15-6, 18-9.

  39. Moffatt C, P. Franks, D. Doherty et al. 2003. Lymphoedema: an underestimated health problem. QJM 96(10): 731– 8

  40. Idem.

  41. Fu, M. R., S. H. Ridner and J. Armer. Op cit.

  42. Thiadens, S.R.J., et al. Op. cit.

  43. Moseley A. L., C. J. Carati, et al. 2007. A systematic review of common conservative therapies for arm lymphedema secondary to breast cancer treatment. Ann Oncol 18(4): 639-46.

  44. Armer J. M., M. E. Radina, et al. Op. cit.

  45. Girones M., M. Arenillas, M. González, L. Salom. 2008. Linfedema: prevención y calidad de vida. Federación española de cáncer de mama/Pfizer. Cap 7:169-186

  46. Shih Y. C., Y. Xu, J. N. Cormier, S. Giordano, S. H. Ridner, T. A. Buchholz, G. H. Perkins and L. S. Elting 2009.. Incidence, treatment costs, and complications of Lymphedema after breast cancer among women of working age: a 2- year follow-up study Journal of clinical oncology, 2009 Apr 20;27(12):2007-14

  47. Girones M., M. Arenillas, M. González, L. Salom. Op. cit.

  48. Armer J. M. Op. Cit.

  49. Armer J. M., M. E. Radina, et al. Op. cit.

  50. Girones M., M. Arenillas, M. González, L. Salom. Op. cit.

  51. Schmitz K. H. Op. cit.

  52. Shih Y. C., et al. Op. cit.

  53. Girones M., M. Arenillas, M. González, L. Salom. Op. cit.

  54. Robles J.I. 2006. “Linfedema: Una patología olvidada”. Psicooncología, 3(1): 71-89.

  55. Secretaria de Salud Norma Oficial Mexicana NOM-041-SSA2.2002. 2008. Para la prevención, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer de mama. 17 Septiembre 2003. Consultado el 25 de julio, 2008. Disponible en: .

  56. Secretaria de Salud Norma Oficial Mexicana, Proyecto de Modificación a la Norma Oficial Mexicana NOM-041- SSA2-2002, Para la prevención, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer de mama; para quedar como Proyecto de Norma Oficial Mexicana PROY-NOM-041-SSA2-2009, Para la prevención, diagnóstico, tratamiento, control y vigilancia del cáncer de mama. Consultado el 21 de Enero del 2011. Disponible en:

  57. Armer J. M., M. E. Radina, et al. Op. cit.

  58. Ridner S. H., L. D. Montgomery, et al. 2007. Comparison of upper limb volume measurement techniques and arm symptoms between healthy volunteers and individuals with known lymphedema. Lymphology 40(1): 35-46.

  59. Armer J. M., M. E. Radina, et al. Op. cit.

  60. Schmitz K. H. Op. cit.

  61. Armer J. M. and B. R. Stewart. Op. cit.

  62. Armer J. M. Op. Cit.

  63. Armer J. M., M. E. Radina, et al. Op. cit.

  64. Armer J. M. and B. R. Stewart. Op. cit.

  65. Ridner S. H., L. D. Montgomery, et al. Op. cit.

  66. Idem.

  67. Cormier J. N., et al. Op. cit.

  68. Hayes S.C., M. Janda, B. Cornish, D. Battistutta, B. Newman. 2008. Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol. 2008 Jul 20; 26(21):3536-42.

  69. Armer J. M. and B. R. Stewart. Op. cit.

  70. Armer J. M., M. E. Radina, et al. Op. cit.

  71. Fu M. R., S. H. Ridner and J. Armer. Op cit.

  72. Fleysher L.A. Op. cit.




2020     |     www.medigraphic.com